Related Experiment Video
Updated: Feb 28, 2026

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
Published on: June 29, 2019
Clinical Evidence Linking the Gut Microbiome and Functional Dyspepsia: A Systematic Review and Meta-Analysis
Kyungjae Lee1, Hojun Kim2, Jing-Hua Wang3
1College of Korean Medicine, Dongguk University, 32 Dongguk-ro, Ilsandong-gu, Goyang-si 10326, Gyeonggi-do, Republic of Korea.
Functional dyspepsia (FD) shows no significant gut microbiota differences between patients and controls. However, interventions improved symptoms by altering the gut microbial community and increasing short-chain fatty acids (SCFAs).
Area of Science:
- Gastroenterology
- Microbiome Research
- Metabolomics
Background:
- The gut microbiome is increasingly implicated in functional dyspepsia (FD).
- The exact relationship between gut microbiota and FD pathophysiology remains unclear.
- This study systematically reviews and meta-analyzes the gut microbiome's role in FD.
Purpose of the Study:
- To investigate the gut microbiome's role in functional dyspepsia (FD).
- To analyze differences in gut microbiota between FD patients and healthy individuals.
- To assess the impact of interventions on the gut microbiome in FD.
Main Methods:
- A systematic literature search was performed across PubMed, Google Scholar, and Web of Science.
- 17 clinical studies (8 observational, 9 interventional) published up to September 2025 were included.
- Meta-analysis was used to synthesize data on gut microbiota and FD.
Main Results:
- No significant differences in gut microbiota diversity (α or β) were found between FD patients and healthy controls.
- Interventions led to significant shifts in microbial community structure.
- These microbial shifts correlated with increased short-chain fatty acid (SCFA) production and improved FD symptoms.
Conclusions:
- While baseline gut microbiota composition doesn't differ significantly in FD, interventions can induce substantial microbial changes.
- Modulating gut microbiota and its metabolites, like SCFAs, presents a potential therapeutic avenue for FD management.
Related Concept Videos
Assessment of the Gastrointestinal System I: Subjective Data
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...

